ArticleACS omega2025
Optimization of Zein-Casein-Hyaluronic Acid Nanoparticles Obtained by Nanoprecipitation Using Design of Experiments (DoE).
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Olmesartan-Loaded PLGA Nanoparticles Attenuate Methotrexate-Induced Kidney Injury: Association with the AT1R/ERK1/2 Signaling Axis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Factorial Design-Driven Optimization of Zein-Chitosan Nanoparticles for Oral Delivery of Silibinin.ACS omega · 2026Article
- Evaluation of the antiviral effect of casein nanoparticles (CNP) loaded with Plantago major extract (PME-CNP) on herpes simplex virus.Virology journal · 2026Article
- Therapeutic Approach Based on Nanotechnology with Chitosan-Coated Zein Nanoparticles Containing Quercetin Against ResistantPharmaceutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zein-based nanoparticles offer significant potential as carriers for drug delivery due to their biocompatibility. However, optimizing their formulation is essential to achieving efficient encapsulation and stability. This study aimed to optimize the formulation of zein-casein-hyaluronic acid-based nanoparticles for the encapsulation of a hydrophilic drug, focusing on achieving favorable physicochemical properties for oral drug delivery applications. A factorial experimental design was employed to evaluate the influence of key formulation parameters, including zein concentration, hyaluronic acid concentration, sodium caseinate concentration, and the organic-to-aqueous phase (O/W) ratio. Particle size (PS), polydispersity index (PDI), zeta potential, and encapsulation efficiency (EE) were analyzed as response variables. Multivariate analyses, such as hierarchical cluster analysis and principal component analysis, were performed to explore the relationships between formulation parameters and nanoparticle properties. Model validity was confirmed by using ANOVA and residual analysis. Optimized nanoparticles exhibited a PS of 217 ± 5 nm, PDI of 0.077 ± 0.022, zeta potential of -24.7 ± 1.9 mV, and EE of 31% ± 4. The nanoparticles displayed a monomodal size distribution and a spherical morphology. Multivariate analyses revealed that the O/W ratio and zein concentration were the most influential factors, while sodium caseinate played a crucial stabilizing role. The desirability function yielded a high score (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.